Table 1.
Positive phase III trials of cytotoxic agents in second line metastatic cancers
| Ref. | Patients/phase | Treatment | Indication | Results (PFS/OS/RR) (mo) |
| Ford et al[18], 2014 | 168/III | Docetaxel | Advanced, gastric cancer that had progressed on or within 6 mo of treatment with a platinum-fluoropyrimidine combination | OS: 5.2 |
| COUGAR-02 | Active symptom control | OS: 3.6 | ||
| Kang et al[28], 2012[28] | 202/III | Docetaxel | Advanced gastric cancer with one or two prior chemotherapy regimens involving both fluoropyrimidines and platinum | 5.2 |
| Irinotecan | 6.5 | |||
| BSC | 3.8 |